Show simple item record

dc.contributor.authorThomas, Robert
dc.contributor.authorWilliams, Madeleine
dc.contributor.authorAldous, Jeffrey William Frederick
dc.contributor.authorYanagisawa, Yuuki
dc.contributor.authorKumar, Rajeev
dc.contributor.authorForsyth, Rachel
dc.contributor.authorChater, Angel M.
dc.contributor.illustrator
dc.date.accessioned2022-03-29T08:27:28Z
dc.date.available2022-03-22T00:00:00Z
dc.date.available2022-03-29T08:27:28Z
dc.date.issued2022-03-22
dc.identifier.citationThomas R, Williams M, Aldous J, Yanagisawa Y, Kumar R, Forsyth R, Chater A (2022) 'A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19— The UK Phyto-V Study', COVID, 2 (4), pp.433-449.en_US
dc.identifier.doi10.3390/covid2040031
dc.identifier.urihttp://hdl.handle.net/10547/625358
dc.description.abstractGut microflora dysbiosis affects the majority of individuals after COVID-19, contributing to both gastro-intestinal (GI) and non-GI symptoms. Natural phytochemicals have reported anti-viral properties and favourable effects on inflammatory and oxidative pathways, both important for tissue damage post-viral pneumonia. This study involved 147 participants with symptomatic COVID-19, randomised to receive a placebo (P) or a phytochemical-rich concentrated food capsule (PC) in addition to a pre/probiotic lactobacillus capsule. Participants taking the PC had an almost two-fold reduction in mean fatigue scores compared to P [p = 0.02], a three-fold reduction in cough score and more than a double improvement in overall well-being scores [p = 0.02]. Two (1.5%) participants reported mild, increased bloating which they felt was attributable to the capsules, although GI symptoms improved in 25 of 31 participants (82%) who reported them at baseline. Sedentary, older, previously hospitalised men with GI symptoms had a statistically significantly improvement among those given the probiotic. Although some participants with early disease would have improved spontaneously, such a rapid improvement observed in the majority of participants, who had been suffering for an average of 108 days, was clinically relevant and welcomed, especially among those more likely to have pre-existing gut dysbiosis. We are now evaluating whether this blend could also enhance antibody titres post-COVID-19 vaccination.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.urlhttps://www.mdpi.com/2673-8112/2/4/31en_US
dc.rights
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectprobioticsen_US
dc.subjectCovid-19en_US
dc.subjectgut healthen_US
dc.subjectLong Covid-19en_US
dc.titleA randomised, double-blind, placebo-controlled trial evaluating concentrated phytochemical-rich nutritional capsule in addition to a probiotic capsule on clinical outcomes among individuals with COVID-19— the UK Phyto-V Studyen_US
dc.typeArticleen_US
dc.identifier.eissn2673-8112
dc.contributor.departmentBedfordshire Hospital NHS Trustsen_US
dc.contributor.departmentUniversity of Bedfordshireen_US
dc.contributor.departmentCambridge Universityen_US
dc.identifier.journalCOVIDen_US
dc.date.updated2022-03-29T08:06:06Z
dc.description.noteGold open access journal - will put version of record in repository.
refterms.dateFOA2022-03-29T08:27:29Z


Files in this item

Thumbnail
Name:
covid-02-00031.pdf
Size:
3.324Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as